Last reviewed · How we verify
LY900021
At a glance
| Generic name | LY900021 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LY3074828 in Healthy Participants (PHASE1)
- A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY900021 CI brief — competitive landscape report
- LY900021 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI